Nektarios Barabutis, Agnieszka Siejka, Mohammad S Akhter
Growth Hormone-Releasing Hormone (GHRH) is a hypothalamic peptide which regulates the release of Growth Hormone from the anterior pituitary gland, and has been involved in inflammatory processes. On the other hand, GHRH antagonists (GHRHAnt) were developed to counteract those effects. Herein we demonstrate for the first time that GHRHAnt can suppress hydrogen peroxide (H2 O2 ) - induced paracellular hyperpermeability in bovine pulmonary artery endothelial cells. Increased production of reactive oxygen species (ROS) and barrier dysfunction have been associated with the development of potentially lethal disorders, including sepsis and acute respiratory distress syndrome (ARDS)...
May 18, 2023: Growth Hormone & IGF Research
Fengping Sun, Liqin Chao, Junxia Zhang, Xiaoli Pan
OBJECTIVE: This study was aimed to systematically determine the effect of exercise combined with lysine-inositol vitamin B12 (VB12) therapy on the height of children with idiopathic short stature (ISS). METHODS: Sixty children with ISS were randomly divided into observation and control groups (N = 30). Each group was given lysine-inositol VB12 oral solution (10 mL bid). Simultaneously, the observation group exercised following the "ISS exercise instruction sheet"...
May 16, 2023: Growth Hormone & IGF Research
Rachel Barker, Kalina Biernacka, Georgina Kingshott, Alex Sewell, Paida Gwiti, Richard M Martin, J Athene Lane, Lucy McGeagh, Anthony Koupparis, Edward Rowe, Jon Oxley, Claire M Perks, Jeff M P Holly
AIMS: To examine associations between the transcription factors CCCTC-binding factor (CTCF) and forkhead box protein A1 (FOXA1) and the androgen receptor (AR) and their association with components of the insulin-like growth factor (IGF)-pathway in a cohort of men with localized prostate cancer. METHODS: Using prostate tissue samples collected during the Prostate cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) trial (N = 70 to 92, depending on section availability), we assessed the abundance of CTCF, FOXA1, AR, IGFIR, p-mTOR, PTEN and IGFBP-2 proteins using a modified version of the Allred scoring system...
April 14, 2023: Growth Hormone & IGF Research
Helena-Jamin Ly, Anders Lindberg, Hans Fors, Jovanna Dahlgren
OBJECTIVE: Prediction models that calculate the growth response in children on recombinant growth hormone (GH) have shown to be helpful tools in deciding who should start treatment, as identifying GH deficiency can be a challenge. The aim of the study is to compare two prediction models; the KIGS (Pfizer International Growth Study) prediction models which are more accessible and the Gothenburg model which has previously been clinically validated. DESIGN: All prepubertal patients who commenced GH treatment at Queen Silvia Children's Hospital in Gothenburg during a 13-year-period were candidates for the study...
February 2023: Growth Hormone & IGF Research
Giorgio Sodero, Francesco Mariani, Michela Caprarelli, Cristiana Agazzi, Ludovica Quarta, Luca Benacquista, Donato Rigante, Cipolla Clelia
BACKGROUND: Children with auxological parameters defining a 'short stature' is routinely subjected to various blood tests and, if necessary, to growth hormone stimulation test (GHST) for differentiating GH deficiency (GHD) and other causes of stunted growth. AIM: This retrospective monocentric study aimed to evaluate any correlations between GH peaks during GHST in children assessed for short stature and their auxological/metabolic parameters, highlighting differences between GHD and idiopathic short stature...
February 2023: Growth Hormone & IGF Research
Emre Urhan, Aysa Hacioglu, Izzet Okcesiz, Zuleyha Karaca, Canan Sehit Kara, Kursad Unluhizarci
OBJECTIVE: We investigated the coexistence of newly diagnosed acromegaly with primary empty sella (ES), which is considered to be a rare association, and the impact of ES on the laboratory, radiological and prognostic status of acromegaly. DESIGN: Acromegaly patients diagnosed and followed-up between 2012 and 2021 were included. Empty sella was defined as the pituitary gland and adenoma filling <50% of the sella turcica on preoperative T1 magnetic resonance imaging (MRI)...
February 2023: Growth Hormone & IGF Research
Mitsunori Miyazaki, Atsushi Sawada, Daisuke Sawamura, Susumu Yoshida
OBJECTIVE: Cachexia is a systemic metabolic syndrome characterized by loss of body weight and skeletal muscle mass during chronic wasting diseases, such as cancer. Skeletal muscle in cancer cachexia is less responsive to anabolic factors including mechanical loading; however, the precise molecular mechanism is largely unknown. In this study, we examined the underlying mechanism of anabolic resistance in skeletal muscle in a cancer cachexia model. METHODS: CD2F1 mice (male, 8 weeks old) were subcutaneously transplanted (1 × 106 cells per mouse) with a mouse colon cancer-derived cell line (C26) as a model of cancer cachexia...
2023: Growth Hormone & IGF Research
Giorgio Sodero, Clelia Cipolla, Lucia Celeste Pane, Linda Sessa, Elena Malavolta, Federica Arzilli, Chiara Leoni, Giuseppe Zampino, Donato Rigante
Patients with Noonan syndrome typically have a target height <2 standard deviations compared to the general population, and half of the affected adults remain permanently below the 3rd centile for height, though their short stature might result from a multifactorial etiology, not-yet fully understood. The secretion of growth hormone (GH) following the classic GH stimulation tests is often normal, with baseline insulin-like growth factor-1 (IGF-1) levels at the lower normal limits, but patients with Noonan syndrome have also a possible moderate response to GH therapy, leading to a final increased height and substantial improvement in growth rate...
2023: Growth Hormone & IGF Research
Kyungchul Song, Mo Kyung Jung, Jun Suk Oh, Su Jin Kim, Han Saem Choi, Myeongseob Lee, Junghwan Suh, Ahreum Kwon, Hyun Wook Chae, Ho-Seong Kim
OBJECTIVE: Growth hormone (GH) dosage in children is conventionally determined either by body weight (BW) or body surface area (BSA). However, there is no consensus on the calculation method for proper GH treatment dose. We aimed to compare growth response and adverse reactions between BW- and BSA-based GH treatment doses for children with short statures. DESIGN: Data from 2284 GH-treated children were analyzed. Distributions of BW- and BSA-based GH treatment doses and their association with growth response parameters, including changes in height, height standard deviation score (SDS), body mass index (BMI), and safety parameters, such as changes in insulin-like growth factor (IGF)-I SDS and adverse events, were investigated...
2023: Growth Hormone & IGF Research
Galina Götherström, Gudmundur Johannsson, Johan Svensson
OBJECTIVE: Little is known of the effects of a fixed very low dose of growth hormone (GH) replacement on cardiovascular risk factors, bone mass, muscle strength and quality of life (QoL) in hypopituitary patients. DESIGN/PATIENTS/METHODS: This was an open-label randomized study performed at a single center. Consecutive hypopituitary patients with adult onset GH deficiency (GHD) and BMI ≥ 27 kg/m<sup>2</sup> were randomized to receive a very low fixed dose of GH (LG, n = 9) or a standard dose of GH (SG, n = 9)...
December 2022: Growth Hormone & IGF Research
Hakan Düğer, Hayri Bostan, Hilal Yıldırım Deryol, Narin Nasıroğlu İmga, Bekir Uçan, Murat Çalapkulu, Sema Hepşen, Pınar Akhanlı, Ümran Gül, Muhammed Erkam Sencar, Erman Çakal, Şeyda Özdemir, Muhammed Kızılgül
BACKGROUND: The nadir growth hormone (nGH) during the oral glucose tolerance test (OGTT) is the gold standard method for diagnosing acromegaly. A paradoxical growth hormone (GH) response to oral glucose (OG) in acromegaly can be observed. The role of the paradoxical GH response on how the patients with acromegaly respond to the treatment has been addressed in few studies. The aim of this study was to investigate the association between glucose-dependent growth hormone results and and the responses of acromegalic patients to surgical and/or medical therapy following surgery...
December 2022: Growth Hormone & IGF Research
Zvi Laron
A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the recently reported association between childhood hGH treatment and cardiovascular morbidity is probably due to the GH effect on Lp(a) synthesis. It is therefore suggested to determine serum Lp(a) levels before and during hGH treatment in children and adults...
December 2022: Growth Hormone & IGF Research
Despoina Myrsini Galetaki, Charles L Cai, Kulsajan S Bhatia, Vivian Chin, Jacob V Aranda, Kay D Beharry
OBJECTIVE: Extremely low gestational age neonates (ELGANs) experience frequent intermittent hypoxia (IH) episodes during therapeutic oxygen. ELGANs exhibit poor postnatal growth requiring lipid supplementation. Lipids are targets of reactive oxygen species resulting in lipid peroxidation and cell death, particularly in preterm infants with compromised antioxidant systems. We tested the hypothesis that early supplementation with lipids and/or antioxidants promotes growth and influences biomarkers of carbohydrate metabolism in neonatal rats exposed to IH...
November 5, 2022: Growth Hormone & IGF Research
S Kalla Singh, Q W Tan, C Brito, M De León, D De León
No abstract text is available yet for this article.
October 21, 2022: Growth Hormone & IGF Research
Kateřina Anderlová, Anna Cinkajzlová, Patrik Šimják, Jana Kloučková, Helena Kratochvílová, Zdeňka Lacinová, Věra Toušková, Hana Krejčí, Miloš Mráz, Antonín Pařízek, Martin Haluzík, Michal Kršek
OBJECTIVE: Insulin-like growth factors (IGFs) are involved in regulating growth and metabolism and increase insulin sensitivity, improve glucose metabolism, and are potentially related to gestational diabetes mellitus (GDM) and its complications for mothers and fetuses. DESIGN: This study aimed to assess serum levels and cord blood levels of IGF system components in pregnant women with (39 participants) and without GDM (22 participants). Blood samples were obtained at 28-32 and 36-38 weeks of gestation and 6-12 months after delivery...
October 3, 2022: Growth Hormone & IGF Research
Elif Tutku Durmuş, Ayşegül Atmaca, Mehmet Kefeli, Sultan Çalışkan, Ozgur Mete, Kerim Aslan, Murat Fidan, Ramis Çolak, Buğra Durmuş
PURPOSE: To determine whether biochemical responses to long-acting forms of first-generation somatostatin analogue (SSA) therapy in patients with acromegaly could be predicted from baseline and postoperative hormone concentrations, and tumor radiological and histopathological characteristics. METHODS: A total of 68 patients with acromegaly for whom postoperative SSA therapy was started were categorized according to their responses to treatment (SSA-responders vs...
September 9, 2022: Growth Hormone & IGF Research
Yasuko Owada, Mika Okazaki, Toshiaki Ikeda, Ryuji Yamamoto, Kohtaro Minami, Kenichi Takahashi, Tohru Hirato, Yoko Mita, Tatsuyoshi Yamamoto, Kazunori Tanizawa, Hiroyuki Sonoda, Yuji Sato
OBJECTIVE: Under clinical development for patients with growth hormone deficiency, JR-142 is a long-acting growth hormone with a half-life extended by fusion with modified serum albumin. We conducted a Phase 1 study to investigate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of once-weekly subcutaneous administrations of JR-142. The study consisted of two parts: an open-label single ascending dosing study (Part 1), and a randomized, placebo-controlled, assessor-blinded multiple ascending dosing study (Part 2)...
September 8, 2022: Growth Hormone & IGF Research
Guanjun Xu, Jiesheng Chu, Yu Shi, Longzhang Huang, Jingzhong Fu
OBJECTIVES: Insulin-like growth factor 1 receptor (IGF-1R) is a transmembrane tyrosine kinase receptor of the insulin receptor family. Its expression is consistently increased in hepatocellular carcinoma (HCC) tissue, and it participates in hepatic carcinogenesis. Targeting IGF-1R may be a potential therapeutic approach against hepatocellular carcinoma. This study therefore aimed to explore the effect of IGF-1R on hepatocellular carcinoma cells. METHODS: IGF-1R silencing cell lines were established by small-interfering RNAs in hepatocellular carcinoma cell line SMMC7721, after which the proliferation, invasion, and apoptosis of SMMC7721 was evaluated...
August 27, 2022: Growth Hormone & IGF Research
Tingting Li, Hui Bai, Haoyuan Fang, Liang Yang, Peishi Yan
OBJECTIVE: It is well established that growth hormone (GH) has the ability to stimulate lipolysis. The effects of GH on adipocyte differentiation and browning have not been clearly described. Therefore, the present study aimed to elucidate the role of GH in the differentiation and browning of bovine subcutaneous adipocytes as well as its underlying molecular mechanisms. METHODS: We first treated bovine subcutaneous preadipocytes with different concentrations (0, 10, 100, and 500 ng/mL) of GH for 8 days and measured lipid accumulation and gene expression...
August 18, 2022: Growth Hormone & IGF Research
Dan Nemet, Sigal Ben-Zaken, Roi A Eliakim, Alon Eliakim
PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) is typically a chronic, often lifelong condition. Data suggest that ADHD itself and its treatment may be associated with dysregulated growth, including height and BMI. The reason for this association is yet unknown. The objective of this study was to examine differences in growth hormone (GH) response to exercise between children who had received a diagnosis of ADHD and age- and gender-matched controls. We reasoned that the normal increase in circulating GH seen in response to exercise would be blunted in children with ADHD...
August 2022: Growth Hormone & IGF Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.